Current status and future directions of molecularly targeted therapies and immunotherapies for melanoma.

Miller, David M

Current status and future directions of molecularly targeted therapies and immunotherapies for melanoma. [electronic resource] - Seminars in cutaneous medicine and surgery Jun 2014 - 60-7 p. digital

Publication Type: Journal Article; Review

1085-5629

10.12788/j.sder.0081 doi


Antineoplastic Agents--therapeutic use
CTLA-4 Antigen--antagonists & inhibitors
Humans
Immunologic Factors--therapeutic use
Immunotherapy
Interferon-alpha--therapeutic use
Interleukin-2--therapeutic use
Melanoma--genetics
Mitogen-Activated Protein Kinase Kinases--antagonists & inhibitors
Molecular Targeted Therapy
Mutation
Programmed Cell Death 1 Receptor--antagonists & inhibitors
Protein Kinase Inhibitors--therapeutic use
Proto-Oncogene Proteins B-raf--antagonists & inhibitors
Proto-Oncogene Proteins c-kit--genetics
Skin Neoplasms--genetics